Carmustine polifeprosan 20 wafer/isotretinoin/temozolomide
- 60 Downloads
An event is serious (based on the ICH definition) when the patient outcome is:
* congenital anomaly
* other medically important event
In a retrospective study of 155 patients diagnosed with glioblastoma between 1 January 1998 and 8 February 2010, 6 patients (4 men and 2 women) aged 30−69 years were described, who developed various second primary cancers following treatment with temozolomide, isotretinoin or carmustine polifeprosan 20 wafer for glioblastoma (GBM) [routes not stated; not all dosages, times to reactions onsets and outcomes stated].
A 69-year-old man developed systemic leukaemia following treatment with temozolomide: The man, who was a long-term survivor in the setting of GBM (GBM diagnosed at the age of 61 years), underwent a gross total resection (GTR) followed by external-beam radiation with adjuvant temozolomide. He completed 12 months of adjuvant temozolomide followed by serial imaging....